Literature DB >> 2847753

Mixed function oxidase and UDP-glucuronyltransferase activities in the human Hep G2 hepatoma cell line.

M H Grant1, S J Duthie, A G Gray, M D Burke.   

Abstract

In cultured human hepatoma cells phenolphthalein glucuronidation was increased 3-fold by 2 mM phenobarbitone (PB) in the culture medium but not by 25 microM benz(a)anthracene (BA), while 1-naphthol glucuronidation was not increased by either PB or BA. Ethoxyresorufin O-deethylation (EROD) was increased 15-fold by BA but not by PB, while the O-dealkylations of pentoxyresorufin (PROD) and benzyloxyresorufin (BROD) were increased by either PB or BA. The BROD activity increased by BA was sensitive to inhibition by alpha-naphthoflavone whereas that induced by PB was not. This suggests induction of different cytochrome P-450 isoenzymes. Control Hep G2 cells had similar glucuronide conjugation and cytochrome reductase activities to freshly isolated human adult hepatocytes, but had lower O-dealkylation and elevated microsomal epoxide hydrolase activities.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2847753     DOI: 10.1016/0006-2952(88)90103-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

1.  In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug.

Authors:  Esther F A Brandon; Rolf W Sparidans; Ronald D van Ooijen; Irma Meijerman; Luis Lopez Lazaro; Ignacio Manzanares; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2007-02       Impact factor: 3.850

2.  Purification and properties of cytochrome P-450-dependent 14 alpha-sterol demethylase from Candida albicans.

Authors:  C A Hitchcock; K Dickinson; S B Brown; E G Evans; D J Adams
Journal:  Biochem J       Date:  1989-10-15       Impact factor: 3.857

3.  Impaired cell functions of hepatocytes incubated with plasma of septic patients.

Authors:  Martin Sauer; Cristof Haubner; Thomas Mencke; Gabriele Nöldge-Schomburg; Steffen Mitzner; Jens Altrichter; Jan Stange
Journal:  Inflamm Res       Date:  2012-02-28       Impact factor: 4.575

4.  Antioxidant status, lipid peroxidation, mixed function oxidase and UDP-glucuronyl transferase activities in livers from control and DOCA-salt hypertensive male Sprague Dawley rats.

Authors:  L Nicod; S Rodriguez; J M Letang; C Viollon-Abadie; A Jacqueson; A Berthelot; L Richert
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

5.  Characterization of the human hepatocellular carcinoma (hepg2) cell line as an in vitro model for cadmium toxicity studies.

Authors:  P F Dehn; C M White; D E Conners; G Shipkey; T A Cumbo
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 May-Jun       Impact factor: 2.416

6.  Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver.

Authors:  S L Nyberg; R P Remmel; H J Mann; M V Peshwa; W S Hu; F B Cerra
Journal:  Ann Surg       Date:  1994-07       Impact factor: 12.969

7.  In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug.

Authors:  Esther F A Brandon; Rolf W Sparidans; Irma Meijerman; Ignasio Manzanares; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850

Review 8.  Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression.

Authors:  Satyanarayana R Pondugula; Hanqing Dong; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-08       Impact factor: 4.481

Review 9.  Human cell lines in pharmacotoxicology. An introduction to a panel discussion.

Authors:  A M Batt; L Ferrari; A Abid; N Sabolović
Journal:  Cell Biol Toxicol       Date:  1995-08       Impact factor: 6.691

10.  Assessment of biological activities of mixtures of polychlorinated dibenzo-p-dioxins (PCDDs) and their constituents in human HepG2 cells.

Authors:  H P Lipp; D Schrenk; T Wiesmüller; H Hagenmaier; K W Bock
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.